New CARs on and off the road: challenges and new developments in CAR-T cell therapy

被引：3
作者：
Wehrli, Marc [1 ,2 ]
Maus, Marcela, V [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Cellular Immunotherapy Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
CURRENT OPINION IN PHARMACOLOGY | 2021年 / 59卷
基金：
瑞士国家科学基金会;
关键词：
ADOPTIVE IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; SAFETY SWITCH; ACTIVATION; DEPLETION; EFFICACY; GENE; MANAGEMENT;
D O I：
10.1016/j.coph.2021.05.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Building on the tremendous success of chimeric antigen receptor T-cell therapy in hematological malignancies, there are efforts under way to overcome the challenges associated with this treatment and expand its application to solid tumors. In this fast-evolving field, new therapeutic options are constantly generated, tested in model systems, and further evaluated in clinical trials. In this review, we provide an overview of recent challenges and developments associated with engineered T cells and chimeric antigen receptor T-cell applications. We report on the most recent progress in hematological malignancies and highlight technical advances for applications in solid tumors.
引用
收藏
页码：116 / 126
页数：11
相关论文
共 72 条
  • [1] Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
    Adusumilli, Prasad S.
    Zauderer, Marjorie Glass
    Rusch, Valerie W.
    O'Cearbhaill, Roisin
    Zhu, Amy
    Ngai, Daniel
    McGee, Erin
    Chintala, Navin
    Messinger, John
    Cheema, Waseem
    Halton, Elizabeth
    Diamonte, Claudia
    Pineda, John
    Vincent, Alain
    Modi, Shanu
    Solomon, Stephen Barnett
    Jones, David Randolph
    Brentjens, Renier J.
    Riviere, Isabelle
    Sadelain, Michel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
    Avanzi, Mauro P.
    Yeku, Oladapo
    Li, Xinghuo
    Wijewarnasuriya, Dinali P.
    van Leeuwen, Dayenne G.
    Cheung, Kenneth
    Park, Hyebin
    Purdon, Terence J.
    Daniyan, Anthony F.
    Spitzer, Matthew H.
    Brentjens, Renier J.
    [J]. CELL REPORTS, 2018, 23 (07): : 2130 - 2141
  • [3] Gene editing for immune cell therapies
    Bailey, Stefanie R.
    Maus, Marcela V.
    [J]. NATURE BIOTECHNOLOGY, 2019, 37 (12) : 1425 - 1434
  • [4] Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
    Brown, Christine E.
    Alizadeh, Darya
    Starr, Renate
    Weng, Lihong
    Wagner, Jamie R.
    Naranjo, Araceli
    Ostberg, Julie R.
    Blanchard, M. Suzette
    Kilpatrick, Julie
    Simpson, Jennifer
    Kurien, Anita
    Priceman, Saul J.
    Wang, Xiuli
    Harshbarger, Todd L.
    D'Apuzzo, Massimo
    Ressler, Julie A.
    Jensen, Michael C.
    Barish, Michael E.
    Chen, Mike
    Portnow, Jana
    Forman, Stephen J.
    Badie, Behnam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) : 2561 - 2569
  • [5] Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-Specific Second-Generation Chimeric Antigen Receptor T Cells in a Mouse Model
    Cheadle, Eleanor J.
    Sheard, Victoria
    Rothwell, Dominic G.
    Bridgeman, John S.
    Ashton, Garry
    Hanson, Vivien
    Mansoor, A. Wasat
    Hawkins, Robert E.
    Gilham, David E.
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 192 (08) : 3654 - 3665
  • [6] CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
    Choi, Bryan D.
    Yu, Xiaoling
    Castano, Ana P.
    Bouffard, Amanda A.
    Schmidts, Andrea
    Larson, Rebecca C.
    Bailey, Stefanie R.
    Boroughs, Angela C.
    Frigault, Matthew J.
    Leick, Mark B.
    Scarfo, Irene
    Cetrulo, Curtis L.
    Demehri, Shadmehr
    Nahed, Brian V.
    Cahill, Daniel P.
    Wakimoto, Hiroaki
    Curry, William T.
    Carter, Bob S.
    Maus, Marcela V.
    [J]. NATURE BIOTECHNOLOGY, 2019, 37 (09) : 1049 - +
  • [7] 'Off-the-shelf' allogeneic CAR T cells: development and challenges
    Depil, S.
    Duchateau, P.
    Grupp, S. A.
    Mufti, G.
    Poirot, L.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 185 - 199
  • [8] Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
    Di Stasi, Antonio
    Tey, Siok-Keen
    Dotti, Gianpietro
    Fujita, Yuriko
    Kennedy-Nasser, Alana
    Martinez, Caridad
    Straathof, Karin
    Liu, Enli
    Durett, April G.
    Grilley, Bambi
    Liu, Hao
    Cruz, Conrad R.
    Savoldo, Barbara
    Gee, Adrian P.
    Schindler, John
    Krance, Robert A.
    Heslop, Helen E.
    Spencer, David M.
    Rooney, Cliona M.
    Brenner, Malcolm K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) : 1673 - 1683
  • [9] A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
    Enblad, Gunilla
    Karlsson, Hannah
    Gammelgard, Gustav
    Wenthe, Jessica
    Lovgren, Tanja
    Amini, Rose Marie
    Wikstrom, Kristina I.
    Essand, Magnus
    Savoldo, Barbara
    Hallbook, Helene
    Hoglund, Martin
    Dotti, Gianpietro
    Brenner, Malcolm K.
    Hagberg, Hans
    Loskog, Angelica
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6185 - 6194
  • [10] PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
    Fedorov, Victor D.
    Themeli, Maria
    Sadelain, Michel
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (215)
12345678